Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer

Anti-Cancer Drugs

Volumn 19, Issue 3, 2008, Pages 283-288

  Hwang, Wei Shou ^a   Chao, Tsu Yi ^b   Lin, Shen Fung ^e   Chung, Chih Yuan ^f   Chiu, Chang Fang ^g   Chang, Yi Fang ^c   Chen, Po Min ^d   Chiou, Tzeon Jye ^d,h  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Advanced gastric cancer; Continuous infusion of 5 fluorouracil leucovorin; Efficacy; Oxaliplatin; Toxicity

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; DISEASE COURSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; REMISSION; STOMACH TUMOR; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

EID: 45549090652     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3282f3fd17     Document Type: Article

References (32)

1. Department of Health, Executive Yuan, Taiwan, Republic of China. The main causes of death in Taiwan in 2000. Available: http://www.doh.gov.tw.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41.
3. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587-591.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163-168.
5. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19:29-44.
6. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813-3818.
7. Coombes R, Chilvers CE, Amadori D, Medi F, Fountzilas G, Rauschecker H, et al. Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer: an International Collaborative Cancer Group (ICCG) study. Ann Oncol 1994; 5:33-36.
8. Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, et al. Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996; 78:1888-1891.
9. Louvet C, de Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol 1991; 2:229-230.
10. Johnson P, Thompson PI, Seymour M, Deasy NP, Thuraisingham RC, Slevin ML, et al. A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 1991; 64:603-605.
11. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91:453-458.
12. Chiou TJ, Kung SP, Hsieh RK, Fan S, Tzeng CH, Wei CH, et al. Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/ 5-flurouracil. Cancer Invest 1996; 14:197-201.
13. Chiou TJ, Tung SL, Hsieh RK, Wang WS, Yen CC, Fan FS, et al. Phase II study of the modified regimen of etoposide, leucovorin and 5-flurouracil for patients with advanced gastric cancer. Jpn J Clin Oncol 1998; 28:318-322.
14. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefolih S, Oliveica J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30:1263-1269.
15. Ychou M, Astre C, Rouanet P, Fabre JM, Saint-Aubert B, Domergue J, et al. A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 1996; 32:1933-1937.
16. Lin WL, Li DG, Chen Q, Lu HM. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 2004; 10:2911-2915.
17. Lévi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian-rhythm modulated rate. Eur J Cancer 1993; 29A:1280-1284.
18. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7:95-98.
19. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzhaki M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, volinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69:893-900.
20. Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86:1608-1617.
21. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucoverin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
22. Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001; 20:124a (abstract 494).
23. Eriguchi M, Osada I, Fujii Y, Takeda Y, Yoshizaki I, Akiyama N, et al. Pilot study for preoperative administration of 1-OHP to patients with advanced scirrhous type gastric cancer. Biomed Pharmacother 1997; 51:217-220.
24. Louvet C, Andre T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543-4548.
25. Al-Batran SE, Atmaka A, Hegewisc-Becker S, Jaeger D, Hahnfeld S, Rummel MJ, et al. Phase II trial of biweekly infusional fluouracil, folinic acid and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658-663.
26. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 92:1644-1649.
27. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-13.
28. Oh SY, Kwon HC, SEO BG, Kim SH, Kim JS, Kim HJ. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007; 46:336-341.
29. Chen JS. A Multiple Centre Phase II Study of Biweekly Oxalipaltin (OXA) and Tegafur-Uracil/Leucorvin (LV) in Chemonaive Patients with Advanced Gastric Cancer. The 7th International Conference of the Asian Clinical Oncol Society.
30. Santini D, Vincenzi B, Schiavon G, Di Seri M, Virzí V, Spalletta B, et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: a phase II study. Cancer Chemother Pharmacol 2007; 59:613-620.
31. Al-Batran SE, Hartmann JT, Probst S, Hofheinz R, Stoehlmacher H, Schmalenberg J, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) [abstract]. Proc Am Soc Clin Oncol 2006; 24 (18 Suppl):LBA4016.
32. Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, et al. Randomized, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: the REAL 2 trial. Proc Am Soc Clin Oncol 2006; 24 (18 Suppl):LBA4017.